Scarica l'app Stockscreener
11.46
4.18%
-0.50
Pre-mercato:
11.62
0.16
+1.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.96
Aprire:
$11.84
Volume 24 ore:
1.52M
Relative Volume:
1.32
Capitalizzazione di mercato:
$829.42M
Reddito:
-
Utile/perdita netta:
$-4.81M
Rapporto P/E:
-22.93
EPS:
-0.4998
Flusso di cassa netto:
$-122.54M
1 W Prestazione:
-6.45%
1M Prestazione:
-14.29%
6M Prestazione:
+29.20%
1 anno Prestazione:
+255.90%
Intervallo 1D:
$11.46
$11.97
Intervallo di 1 settimana:
$11.41
$12.55
Portata 52W:
$2.95
$17.65
Omeros Corp Stock (OMER) Company Profile
Nome
Omeros Corp
Settore
Industria
Telefono
206-676-5000
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
11.46 | 865.61M | 0 | -4.81M | -122.54M | -0.4998 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2022-12-08 | Downgrade | UBS | Buy → Neutral |
| 2022-11-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Downgrade | Maxim Group | Buy → Hold |
| 2021-10-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-09-27 | Iniziato | JP Morgan | Neutral |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-08-21 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2019-05-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-03-05 | Downgrade | Needham | Buy → Hold |
| 2017-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Reiterato | Maxim Group | Buy |
| 2017-03-17 | Reiterato | Needham | Buy |
| 2016-11-16 | Reiterato | Wedbush | Outperform |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-06-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-02 | Reiterato | Needham | Buy |
| 2016-02-29 | Reiterato | Wedbush | Outperform |
| 2015-11-11 | Reiterato | Needham | Buy |
| 2015-08-18 | Reiterato | WBB Securities | Strong Buy |
| 2015-08-10 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Omeros Corp Borsa (OMER) Ultime notizie
Why did Omeros stock jump 5% in after-hours trading today? - MSN
[144] OMEROS CORP SEC Filing - Stock Titan
OMER Technical Analysis & Stock Price Forecast - Intellectia AI
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA - MSN
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss - Investing.com
OMER Stock Price, Quote & Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
Seattle InnoSEngine headed to Bothell I An update on Omeros - The Business Journals
Omeros Corporation (NASDAQ:OMER) Q1 2026 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Q1 2026 Earnings Transcript - The Globe and Mail
OMER Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Omeros Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Omeros (OMER) Reports Strong Q1 2026 Earnings and Positive Cash Flow from YARTEMLEA - GuruFocus
Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YART - GuruFocus
OMER SWOT Analysis: Key Insights from Q1 2026 10-Q Filing - GuruFocus
Omeros Q1 Earnings Call Highlights - Barchart
How Should Investors Value Omeros (OMER) After Q1 2026 EPS $0.62 - GuruFocus
Omeros (OMER) Reports Q1 Revenue and Highlights Growth Initiativ - GuruFocus
Omeros Q1 2026 Earnings Call Transcript - MarketBeat
Omeros earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Omeros misses Q1 2026 expectations, stock dips - Investing.com
Omeros Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts - ChartMill
OMEROS ($OMER) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Omeros Corp Earnings Call Transcript - GuruFocus
Omeros: Q1 Earnings Snapshot - Barchart.com
YARTEMLEA launch and zaltenibart deal reshape Omeros (NASDAQ: OMER) - Stock Titan
Omeros (NASDAQ: OMER) turns Q1 profit on YARTEMLEA sales and CMS gains - Stock Titan
New transplant drug gains Medicare billing code, logs $11M sales - Stock Titan
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 - BioSpace
TradingKey - TradingKey
Omeros earnings up next as investors eye YARTEMLEA launch By Investing.com - Investing.com South Africa
100% Of This Omeros Insider's Holdings Were Sold - Moomoo
OMER stock on track for best week in nearly 4 months after receiving permanent reimbursement code for treatment - MSN
UBS Group AG Grows Position in Omeros Corporation $OMER - MarketBeat
MSN Money - MSN
Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects - simplywall.st
Omeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
OMEROS CORP ($OMER) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, incentives and votes detailed in Omeros (NASDAQ: OMER) 2026 proxy - Stock Titan
[ARS] OMEROS CORP SEC Filing - Stock Titan
Omeros rises as Novo deal boosts Q4 earnings - MSN
OMER stock surges 5% after hours on Novo Nordisk deal windfall and drug launch optimism - MSN
Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway - Yahoo Finance
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside - MSN
Omeros (NASDAQ:OMER) Trading 6.3% HigherShould You Buy? - MarketBeat
Here's Why Omeros (OMER) is a Great Momentum Stock to Buy - Yahoo Finance
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade - Yahoo Finance
Omeros Corp Azioni (OMER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Omeros Corp Azioni (OMER) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Demopulos Gregory A MD | Chairman, CEO & President |
Feb 18 '26 |
Option Exercise |
10.27 |
400,000 |
4,108,000 |
1,826,986 |
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Option Exercise |
3.06 |
30,000 |
91,800 |
30,000 |
| Borges David J. | VP, Finance & CAO |
Jan 12 '26 |
Sale |
12.72 |
30,000 |
381,600 |
0 |
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Sale |
12.31 |
30,000 |
369,315 |
0 |
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):